RxDoctor Payments Data

Vanderbilt Robison, DO

Psychiatry · Bradenton, FLNPI 1972950491

Payments from drug & device makers

$1,037in general payments, 2019–2025

Across 44 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$279
  • Neurocrine Biosciences, Inc.$192
  • Lundbeck LLC$139
  • Idorsia Pharmaceuticals US Inc$124
  • Boston Scientific$116
  • Johnson & Johnson$85
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$1,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,037 in reported general payments places this provider in the 60th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$75,429
Medicare patients
112
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$124,606
Aripiprazole101$13,811
Vilazodone Hcl17$6,916
VyvanseLisdexamfetamine Dimesylate16$6,160
Lisdexamfetamine Dimesylate17$3,555
Duloxetine Hcl165$3,036
Bupropion XlBupropion Hcl155$2,997
Clonazepam216$2,160
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine55$1,923
Alprazolam272$1,759
Venlafaxine Hcl ErVenlafaxine Hcl92$1,709
Lorazepam168$1,708
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine26$1,677
Mirtazapine149$1,607
Paliperidone ErPaliperidone15$1,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$33$6,16016 claims
Almatica Pharma LLCSertraline Hcl$17$1,212143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →